RS-67,506
RS-67,506 is a pharmacological compound that acts as a selective 5-HT4 receptor agonist. It has been studied for its potential effects on gastrointestinal motility and cognitive function.
Pharmacology[edit | edit source]
RS-67,506 is known for its high affinity and selectivity for the 5-HT4 receptor, a subtype of the serotonin receptor family. The activation of 5-HT4 receptors is associated with increased acetylcholine release in the central nervous system, which can enhance cognitive processes such as learning and memory.
Mechanism of Action[edit | edit source]
RS-67,506 binds to the 5-HT4 receptor, which is a G protein-coupled receptor (GPCR). Upon binding, it activates the receptor, leading to the stimulation of adenylate cyclase and an increase in cyclic AMP (cAMP) levels. This cascade results in enhanced neurotransmitter release, particularly acetylcholine, which is crucial for cognitive function and gastrointestinal motility.
Therapeutic Potential[edit | edit source]
The compound has been investigated for its potential use in treating conditions such as irritable bowel syndrome (IBS) and Alzheimer's disease. Its ability to enhance gastrointestinal motility makes it a candidate for treating disorders characterized by reduced motility, while its cognitive-enhancing effects suggest potential benefits in neurodegenerative diseases.
Research and Development[edit | edit source]
RS-67,506 has been the subject of various preclinical studies. These studies have demonstrated its efficacy in enhancing memory and learning in animal models. However, further research is needed to fully understand its safety profile and therapeutic potential in humans.
Safety and Side Effects[edit | edit source]
As with many pharmacological agents, the safety and side effect profile of RS-67,506 is an important consideration. Common side effects observed in preclinical studies include gastrointestinal disturbances and potential cardiovascular effects due to its action on serotonin receptors.
Also see[edit | edit source]
- 5-HT4 receptor
- Serotonin receptor
- Gastrointestinal motility
- Cognitive enhancement
- Alzheimer's disease
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
